Prognostic Groups of Tennant et al for Patients with Myelodysplasia

Description

Tennant et al identified risk groups in patients with myelodysplasia. This can help identify patients who may benefit from more aggressive management. The authors are from the University of Wales in Cardiff.

Initial groups:

(1) marrow myeloblasts < 5%, mean corpuscular volume (MCV) < 100 fL

(2) marrow myeloblasts < 5%, MCV >= 100 fL

(3) marrow myeloblasts >= 5%, MCV < 100 fL

(4) marrow myeloblasts >= 5%, MCV >= 100 fL

Group 1: Marrow myeloblasts < 5%, MCV < 100 fL

Parameter	Finding	Points
hemoglobin	>= 11 g/dL	0
	9.0 - 10.9 g/dL	6
	7.0 - 8.9 g/dL	12
	< 7.0 g/dL	18
MCV	< 85 fL	27
	85 - 89 fL	18
	90 - 94 fL	9
	95 - 99 fL	0
age in years	< 60 years	0
	60 - 67 years	6
	68 - 75 years	12
	> 75 years	18

Group 2: Marrow myeloblasts < 5%, MCV >= 100 fL

Parameter	Finding	Points
hemoglobin	>= 11 g/dL	0
	9.0 - 10.9 g/dL	25
	7.0 - 8.9 g/dL	50
	< 7.0 g/dL	75
percent marrow myeloblasts	0	0
	1%	12
	2%	24
	3%	36
	4%	48
age in years	< 60 years	0
	60 - 67 years	15
	68 - 75 years	30
	> 75 years	45

Group 3: Marrow myeloblasts >= 5%, MCV < 100 fL

Parameter	Finding	Points
IPSS karyotype score	0	0
	0.5	4
	1.0	8
percent marrow myeloblasts	5 - 9%	0
	10 - 16%	5
	17 - 24%	10
	> 24%	15

where:

• A good IPSS karyotype is normal, Y(-), del(5q), del(20q). A poor karyotype has >= 3 abnormalities or an abnormality in chromosome 7. All other karyotypes are intermediate.

• The points for the IPSS karyotype score = (score) * 8

Group 4: Marrow myeloblasts >= 5%, MCV >= 100 fL

Parameter	Finding	Points
age at diagnosis	< 65 years of age	0
	65 - 69 years	10
	70 - 74 years	20
	>= 75 years	30
platelet count	>= 300,000 per µL	0
	200,000 - 299,999 per µL	15
	100,000 - 199,999 per µL	30
	< 100,000 per µL	45

total score =

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10